BTLA

BTLA

BTLA Overview

Molecule Name
B- and T-lymphocyte attenuator
Synonyms
BTLA,CD272
Drug Development Progress
Drugs in Clinical Trials6
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
BTLA,B- and T-lymphocyte attenuator,B- and T-lymphocyte-associated protein,B And T Lymphocyte Associated,CD272 Antigen,BTLA1,CD272
Background
B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

BTLA Product List

Species
  • Human(9)
  • Mouse(1)
Tag
  • Fc Tag(3)
  • His Tag(3)
  • His Tag & Avi Tag(2)
  • Fc Tag & Avi Tag(1)
  • Mouse IgG Fc Tag(1)
Host
  • HEK293(10)
Conjugate
  • Unconjugated(7)
  • Biotin-labeled(3)
Grade
  • RUO(10)
Low Endotoxin
  • Yes(2)
  • No(8)
You Have Viewed 1-10 Of 10 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
TifcemalimabJS-004; TAB-004Phase 3 ClinicalShanghai Junshi Biosciences Co Ltd
Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphoma; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
MB-272MB272; GS-0272Phase 1 ClinicalMiroBio Ltd, University Of Oxford
Arthritis, Rheumatoid; Autoimmune Diseases
Details
ANB-032ANB-032Phase 1 ClinicalAnaptysbio Inc
Dermatitis, Atopic; Eczema; Inflammation
Details
VenanprubartLY-3361237Phase 1 ClinicalEli Lilly And Company, Sanford-Burnham Medical Research Institute
Lupus Erythematosus, Systemic; Psoriasis; Sjogren's Syndrome
Details
HFB200604 AIDHFB-200604-AID; HFB200604; HFB-200604; HFB200604 AIDPhase 1 ClinicalHiFiBiO Therapeutics
Autoimmune Diseases; Inflammation
Details
HFB-200603HFB-200603Phase 1 ClinicalHiFiBiO Therapeutics
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Neoplasms; Stomach Neoplasms
Details
Customer Reviews